Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 3/2019 | Gencove | Seed Round | 3M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 7/2021 | Deep Genomics | Series C | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 3/2017 | EGenesis | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 6/2018 | StrideBio | Series A | 15.7M |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 7/2021 | IgGenix | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 11/2019 | Genetron Health | Series D | 71M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 4/2018 | QurAlis | Seed Round | - |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 10/2021 | DNA Script | Series C | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 11/2018 | Ribometrix | Series A | 30M |
| 6/2018 | Cibus | Series C | 70M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 4/2019 | Insitro | Series A | 100M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 2/2021 | Ensoma | Series A | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 10/2020 | Dren Bio | Series A | 0 |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 9/2018 | Benson Hill | Series C | 65M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 4/2021 | SeQure DX | Series A | 0 |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2021 | Encodia | Series C | 75M |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 5/2022 | Pleno | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 8/2021 | Humacyte | PIPE | 175M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 5/2021 | Inari | Series D | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2021 | Kytopen | Series A | 0 |
| 4/2023 | Function Oncology | Series A | 28M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
